X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (23731) 23731
Magazine Article (225) 225
Publication (23) 23
Book / eBook (16) 16
Book Review (11) 11
Conference Proceeding (11) 11
Reference (7) 7
Newsletter (5) 5
Government Document (4) 4
Dissertation (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22302) 22302
adrenergic beta-antagonists - therapeutic use (20921) 20921
male (10810) 10810
female (10061) 10061
middle aged (8000) 8000
aged (6603) 6603
adult (5406) 5406
hypertension - drug therapy (4427) 4427
cardiac & cardiovascular systems (4199) 4199
angiotensin-converting enzyme inhibitors - therapeutic use (3738) 3738
adrenergic beta-antagonists - pharmacology (3263) 3263
treatment outcome (3196) 3196
heart failure - drug therapy (2952) 2952
calcium channel blockers - therapeutic use (2638) 2638
animals (2618) 2618
adrenergic beta-antagonists - adverse effects (2571) 2571
antihypertensive agents - therapeutic use (2530) 2530
mortality (2371) 2371
drug therapy, combination (2367) 2367
adrenergic beta-antagonists - administration & dosage (2243) 2243
pharmacology & pharmacy (2178) 2178
propanolamines - therapeutic use (2158) 2158
blood pressure - drug effects (2118) 2118
risk factors (2108) 2108
propranolol - therapeutic use (2066) 2066
heart rate - drug effects (2009) 2009
medicine, general & internal (1988) 1988
diuretics - therapeutic use (1945) 1945
heart failure (1796) 1796
hypertension (1775) 1775
time factors (1688) 1688
myocardial infarction - drug therapy (1628) 1628
electrocardiography (1593) 1593
clinical trials as topic (1588) 1588
aged, 80 and over (1558) 1558
follow-up studies (1523) 1523
double-blind method (1395) 1395
prognosis (1343) 1343
retrospective studies (1298) 1298
prospective studies (1295) 1295
beta-blockers (1294) 1294
carvedilol (1260) 1260
drug therapy (1234) 1234
anti-arrhythmia agents - therapeutic use (1206) 1206
angina pectoris - drug therapy (1177) 1177
hemodynamics - drug effects (1173) 1173
heart failure - physiopathology (1171) 1171
propranolol (1165) 1165
hypertension - physiopathology (1162) 1162
vasodilator agents - therapeutic use (1140) 1140
therapy (1119) 1119
carbazoles - therapeutic use (1107) 1107
adolescent (1087) 1087
randomized controlled trials as topic (1083) 1083
peripheral vascular disease (1069) 1069
metoprolol - therapeutic use (1062) 1062
care and treatment (1060) 1060
risk (1011) 1011
management (997) 997
abridged index medicus (938) 938
coronary disease - drug therapy (930) 930
hypertension - complications (927) 927
metoprolol (922) 922
dose-response relationship, drug (910) 910
rats (897) 897
atenolol - therapeutic use (844) 844
blood pressure (826) 826
chronic disease (825) 825
prevention (809) 809
heart failure - mortality (785) 785
myocardial-infarction (785) 785
medicine & public health (753) 753
arrhythmias, cardiac - drug therapy (749) 749
double-blind (743) 743
practice guidelines as topic (743) 743
child (741) 741
cardiology (737) 737
aspirin - therapeutic use (732) 732
exercise test (723) 723
heart rate (723) 723
surgery (722) 722
acute myocardial-infarction (720) 720
survival (715) 715
cardiovascular (696) 696
age factors (689) 689
echocardiography (678) 678
propranolol - pharmacology (671) 671
platelet aggregation inhibitors - therapeutic use (651) 651
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (648) 648
myocardial infarction - mortality (633) 633
myocardial infarction - prevention & control (621) 621
analysis (617) 617
trial (616) 616
blood-pressure (612) 612
beta-blocker (605) 605
health aspects (603) 603
propanolamines - pharmacology (588) 588
morbidity (586) 586
adrenergic alpha-antagonists - therapeutic use (581) 581
adrenergic beta blockers (580) 580
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19574) 19574
German (1209) 1209
French (906) 906
Russian (619) 619
Japanese (405) 405
Italian (396) 396
Spanish (279) 279
Polish (166) 166
Chinese (90) 90
Danish (78) 78
Swedish (71) 71
Dutch (70) 70
Norwegian (62) 62
Hungarian (59) 59
Romanian (58) 58
Czech (55) 55
Portuguese (52) 52
Finnish (40) 40
Serbian (24) 24
Bulgarian (20) 20
Hebrew (16) 16
Slovak (16) 16
Croatian (15) 15
Turkish (13) 13
Ukrainian (13) 13
Lithuanian (6) 6
Korean (3) 3
Afrikaans (1) 1
Bosnian (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | MYOCARDIAL-INFARCTION | AVAILABILITY | HEART-FAILURE | SELF-REPORT | ACUTE CORONARY SYNDROMES | MEDICINES | VALIDITY | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2017, Volume 2017, Issue 1, p. CD002003
Background Beta‐blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long‐term beneficial... 
Hypertension | Kidney disease | Treatment: pharmacological | Stroke | Angiotensin Receptor Antagonists | Pharmacological Therapies | Heart Arrest | Atenolol | Randomized Controlled Trials as Topic | General Pharmacotherapies | Calcium Channel Blockers | Coronary Disease | Adrenergic beta‐Antagonists | Diuretics | Beta‐adrenergic blocking agents | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | Angiotensin Receptor Antagonists [therapeutic use] | Antihypertensive Agents [adverse effects; therapeutic use] | NITRIC-OXIDE RELEASE | Humans | Middle Aged | Calcium Channel Blockers [therapeutic use] | MEDICINE, GENERAL & INTERNAL | END-POINT REDUCTION | Adult | CENTRAL BLOOD-PRESSURE | Hypertension [drug therapy; mortality] | ANTIHYPERTENSIVE TREATMENT | Heart Arrest [prevention & control] | CHRONIC HEART-FAILURE | Diuretics [therapeutic use] | Coronary Disease [prevention & control] | RANDOMIZED-TRIAL | CARDIOVASCULAR MORBIDITY | CALCIUM-CHANNEL BLOCKERS | DIRECT RENIN INHIBITOR | Atenolol [therapeutic use] | Aged | Stroke [prevention & control] | Adrenergic beta-Antagonists [adverse effects; therapeutic use] | CORONARY-ARTERY-DISEASE | Stroke - prevention & control | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Atenolol - therapeutic use | Heart Arrest - prevention & control | Adrenergic beta-Antagonists - adverse effects | Diuretics - therapeutic use | Hypertension - mortality | Angiotensin Receptor Antagonists - therapeutic use | Adrenergic beta-Antagonists - therapeutic use
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 12, pp. 1091 - 1099
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10013, pp. 61 - 69
...% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availability or poor affordability... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | Drug Costs | Platelet Aggregation Inhibitors - economics | Cardiovascular Diseases - drug therapy | Humans | Income | Malaysia | Secondary Prevention | Aspirin - supply & distribution | Urban Population | Angiotensin-Converting Enzyme Inhibitors - supply & distribution | Angiotensin-Converting Enzyme Inhibitors - economics | Sweden | Pakistan | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Iran | Rural Population | China | Adrenergic beta-Antagonists - economics | Brazil | Poland | Aspirin - therapeutic use | Aspirin - economics | Chile | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Agents - economics | Colombia | Argentina | Platelet Aggregation Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | United Arab Emirates | Adrenergic beta-Antagonists - supply & distribution | India | Pharmacies | Canada | Cardiovascular Agents - supply & distribution | Cardiovascular Agents - therapeutic use | Bangladesh | Family Characteristics | Developed Countries | Turkey | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | South Africa | Zimbabwe | Developing Countries | Drugs | Prevention | Usage | Cardiovascular diseases | Analysis | Disease prevention | Cardiovascular disease | Costs | Health care access | Preventive medicine | Health risk assessment | Klinisk medicin | Clinical Medicine
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, p. CD001841
...: What class of drug to use first‐line? This review attempted to answer that question. Objectives To quantify the mortality and morbidity effects from different first... 
Hypertension | Kidney disease | Treatment: pharmacological | Stroke | Sodium Chloride Symporter Inhibitors | Pharmacological Therapies | Angiotensin‐Converting Enzyme Inhibitors | Randomized Controlled Trials as Topic | General Pharmacotherapies | Calcium Channel Blockers | Coronary Disease | Adrenergic beta‐Antagonists | Antihypertensive Agents | Heart & circulation | Thiazides | Medicine General & Introductory Medical Sciences | Treatment of essential Hypertension | Angiotensin-Converting Enzyme Inhibitors [therapeutic use] | Antihypertensive Agents [adverse effects; therapeutic use] | Coronary Disease [prevention & control] | Humans | ELDERLY PROGRAM SHEP | CONVERTING-ENZYME-INHIBITION | Sodium Chloride Symporter Inhibitors [therapeutic use] | Adrenergic beta-Antagonists [therapeutic use] | EUROPEAN-WORKING-PARTY | PROSPECTIVELY-DESIGNED OVERVIEWS | Calcium Channel Blockers [therapeutic use] | SERUM URIC-ACID | MEDICINE, GENERAL & INTERNAL | AUSTRALIAN THERAPEUTIC TRIAL | HIGH-BLOOD-PRESSURE | ISOLATED SYSTOLIC HYPERTENSION | PLACEBO-CONTROLLED TRIAL | Stroke [prevention & control] | CORONARY-HEART-DISEASE | Hypertension [drug therapy; mortality] | Stroke - prevention & control | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Sodium Chloride Symporter Inhibitors - therapeutic use | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Thiazides - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Hypertension - mortality | Adrenergic beta-Antagonists - therapeutic use | Thiazides - therapeutic use
Journal Article